Trials / Completed
CompletedNCT02659891
IVIg to Treat BK Viremia in Kidney Transplant Recipients
Immunoglobulin (Privigen®) Therapy to Treat BK Viremia and Prevent Alloimmune Activation in Kidney Transplant Recipients
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Massachusetts General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The overall goal of this study is to rapidly improve clearance of BK viremia with Immunoglobulin (Privigen®) thereby decreasing the potential for formation of alloantibodies in renal transplant recipients that have had immunosuppression reduction due to BK viremia. Our approach is to perform a prospective, randomized, placebo controlled trial intravenous immune globulin (IVIg; Privigen®) plus protocolized immunosuppression reduction versus placebo and protocolized immunosuppression reduction in patients with BK viremia post-kidney transplantation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IVIg | |
| OTHER | Placebo |
Timeline
- Start date
- 2016-05-01
- Primary completion
- 2020-12-10
- Completion
- 2021-03-31
- First posted
- 2016-01-21
- Last updated
- 2021-09-05
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02659891. Inclusion in this directory is not an endorsement.